Alpha-radioimmunotherapy with At-211: Evaluations and imaging on normal tissues and tumors

Sammanfattning: Alpha-radioimmunotherapy (alpha-RIT) is an internal conformal radiotherapy at the cellular level using alpha-particle emitting radionuclides. Alpha-particles have a very short range in tissues (<100 micrometer) and high linear energy transfer (LET), making them highly cytotoxic. Due to these characters alpha- emitters are potentially highly effective in eradication of small tumor cell clusters while at the same time toxicity of the adjacent normal tissue is avoided. Thus, alpha-RIT could be effective in treatment of cancers characterized by micrometastatic and minimal residual disease, e.g. ovarian and prostate cancer. The biological effects of alpha-particles are grossly unknown and demand dedicated methodologies and evaluations for their interpretation. The aim was to evaluate the irradiation effects of the alpha-particle emitter 211At for its use in alpha-RIT, using nude mice. This included studies on tumor efficacy, kidney toxicity and a study describing a novel bioimaging system, the alpha-camera, for assessment of radionuclide tissue distribution. Growth inhibition (GI) after alpha-RIT with 211At on s.c. OVCAR-3-tumors was compared with GI after external irradiation using 60Co. For alpha-RIT, the mice were injected with 211At-MX35-F(Ab’)2 at different activities. The GI was calculated for both irradiations and used to estimate the relative biological effectiveness (RBE) for alpha-RIT on tumors. At GI of 0.37, the RBE was found to be 4.8±0.7. The long-term renal function after alpha-RIT was studied by measuring the glomerular filtration rate (GFR) after injection of 211At-MX35-F(Ab’)2 at different activities. The GFR was measured repeatedly, using plasma clearance of 51Cr-EDTA, up to 67 weeks after treatment. Dose-dependent and time-progressive reductions in GFR were found. For tumor-bearing mice, the kidney doses required for 50% reduction in GFR were 16±3.3 and 7.5±2.4 Gy at 8-30 and 31-67 weeks, respectively. For non-tumor-bearing mice the corresponding doses were 14±4.1 and 11.3±2.3 Gy. The maximum tolerable dose (MTD) to the kidneys (50% reduction in GFR) was 10 Gy. A novel imaging system for ex vivo detection and quantification of alpha-emitters in tissues was developed, using an autoradiographic technique based on a scintillator and CCD for light detection. Initial evaluations of the imaging characteristics showed that the spatial resolution was 35 ±11 micrometer, the uniformity better than 2% and that the image pixel intensity was proportional to radioactivity in the imaged specimens. As examples of applications, the alpha-camera visualized and quantified differences in the tissue activity distributions after alpha-RIT with 211At. For tumors, a very nonuniform distribution of 211At-MX35-F(Ab’)2 was found from 10 mpi to 6 hpi. At 21 hpi the distribution was more uniform. Images of kidney-sections could identify the 211At-distribution in different renal compartments. The ‘cortex-to-whole-kidney-ratio’ varied with time and bioconjugate size. The 211At-MX35-F(Ab’)2 showed a marked retention in the renal cortex, corresponding to a ratio of 1.38±0.3 at 2 hpi. The RBE found (4.8±0.7) gives further support for the use of alpha-particles in targeted radiotherapy. The MTD of 10 Gy suggests that the kidneys will not be the primary dose-limiting organ in alpha-RIT with 211At. The alpha-camera will be an important tool for internal alpha-particle-dosimetry and for the development of alpha-RIT.